Login Register Cart 0
Generic placeholder image

Recent Advances in Inflammation & Allergy Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-2708
ISSN (Online): 2772-2716

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Association of Growth Differentiation Factor 15 with Arterial Stiffness and Endothelial Function in Subpopulations of Patients with Coronary Artery Disease: A Proof-of-Concept Study

Author(s): Konstantinos Mourouzis*, Gerasimos Siasos, Nikoleta Bozini, Evangelos Oikonomou, Marina Zaromitidou, Vasiliki Tsigkou, Eleni Kokkou, Evanthia Bletsa, Panagiota Stampouloglou, Manolis Vavuranakis and Dimitris Tousoulis

Volume 16, Issue 2, 2022

Published on: 24 November, 2022

Page: [107 - 115] Pages: 9

DOI: 10.2174/2772270817666221104120923

Price: $65

Abstract

Background: Growth-differentiation factor-15 (GDF-15) is a biomarker belonging to the transforming growth factor-beta cytokine superfamily, which is linked to many pathological conditions, including inflammation and myocardial injury. Pulse wave velocity (cfPWV) and augmentation index (AIx) are indices of arterial stiffness, which are associated with the severity of coronary artery disease (CAD). Flow-mediated dilatation (FMD) is a well-studied surrogate marker of endothelial-dependent dysfunction and systemic inflammation.

Objective: In this proof-of-concept study, we aimed to investigate the relationship between circulating GDF-15, endothelial dysfunction, and indices of arterial stiffness in different settings of coronary artery disease and myocardial injury.

Methods: In this cross-sectional single-center study, we enrolled patients (n = 22) after interventional treatment for acute myocardial infarction (AMI), patients (n = 11) admitted with chest pain and elevated cardiac enzymes but without evidence of obstructing CAD (MI-NOCAD) in percutaneous coronary angiography (CAG), and patients (n = 20) who underwent CAG according to indications without evident obstructive CAD in CAG (NOCAD). FMD was assessed at the brachial artery. AIx of the central aortic pressure and cfPWV were estimated by applanation tonometry at the radial and carotid-femoral site, respectively, with a validated acquisition system (Sphygmo- Cor, AtCor Medical, Sydney (NSW), Australia). ELISA was used to determine circulating GDF- 15 serum levels (R&D Systems, Minneapolis, MN). Clinical and demographic data and values of routine biochemical biomarkers were obtained. The highest high-sensitive cardiac Troponin I (hsTpnI) value during hospitalization was also recorded. Left ventricular ejection fraction (LVEF) was assessed with a transthoracic echocardiogram.

Results: Patients with AMI were older, had worse LVEF, higher values of hsTpnI and increased circulating GDF-15 levels. Importantly, AMI patients had increased cfPWV values, deteriorated AIx values, blunted FMD and worse serum creatinine levels compared to MI-NOCAD and NOCAD patients, respectively, whereas MI-NOCAD and NOCAD did not differ from each other significantly on these biomarkers. Both AMI and MI-NOCAD patients presented a higher but comparable white blood cell count than NOCAD patients. A strong linear correlation between GDF-15 and cfPWV, hsTpnI, AIx, white blood cell count and creatinine but not with FMD was demonstrated in the general study population.

Conclusion: This proof-of-concept study showed that higher circulating levels of GDF-15, an inflammatory biomarker, were associated significantly with increased arterial stiffness only in AMI patients, whereas elevated GDF-15 demonstrated a linear relationship with the severity of the myocardial injury.

Next »
Graphical Abstract

[1]
Huang H, Chen Z, Li Y, et al. GDF-15 Suppresses Atherosclerosis by Inhibiting oxLDL-Induced Lipid Accumulation and Inflammation in Macrophages. Evid Based Complement Alternat Med 2021; 2021: 1-13.
[http://dx.doi.org/10.1155/2021/6497568] [PMID: 34539804]
[2]
Chan MMY, Santhanakrishnan R, Chong JPC, et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 2016; 18(1): 81-8.
[http://dx.doi.org/10.1002/ejhf.431] [PMID: 26497848]
[3]
Hassanzadeh Daloee S, Nakhaei N, Hassanzadeh Daloee M, Mahmoodi M, Barzegar-Amini M. Evaluation of growth differentiation factor-15 in patients with or without coronary artery disease. Acta Biomed 2021; 92(2): e2021051.
[PMID: 33988174]
[4]
Wang Y, Zhen C, Wang R, Wang G. Growth-differentiation factor-15 predicts adverse cardiac events in patients with acute coronary syndrome: A meta-analysis. Am J Emerg Med 2019; 37(7): 1346-52.
[http://dx.doi.org/10.1016/j.ajem.2019.04.035] [PMID: 31029521]
[5]
Kosum P, Mattanapojanat N, Kongruttanachok N, Ariyachaipanich A. GDF-15: a novel biomarker of heart failure predicts 30-day allcause mortality and 30-day HF rehospitalization in patients with acute heart failure syndrome. Eur Heart J 2022; 43 (Supplement_1).
[6]
Alfaddagh A, Martin SS, Leucker TM, et al. Inflammation and cardiovascular disease: From mechanisms to therapeutics. Am J Prev Cardiol 2020; 4100130.
[http://dx.doi.org/10.1016/j.ajpc.2020.100130] [PMID: 34327481]
[7]
Oikonomou E, Siasos G, Tsigkou V, et al. Coronary artery disease and endothelial dysfunction: novel diagnostic and therapeutic approaches. Curr Med Chem 2020; 27(7): 1052-80.
[http://dx.doi.org/10.2174/0929867326666190830103219] [PMID: 31470773]
[8]
Theofilis P, Sagris M, Oikonomou E, et al. Inflammatory mechanisms contributing to endothelial dysfunction. Biomedicines 2021; 9(7): 781.
[http://dx.doi.org/10.3390/biomedicines9070781] [PMID: 34356845]
[9]
Maruhashi T, Soga J, Fujimura N, et al. Increased arterial stiffness and cardiovascular risk prediction in controlled hypertensive patients with coronary artery disease: post hoc analysis of FMD-J (Flow-mediated Dilation Japan) Study A. Hypertens Res 2020; 43(8): 781-90.
[http://dx.doi.org/10.1038/s41440-020-0420-6] [PMID: 32152482]
[10]
Georgiopoulos G, Papaioannou TG, Magkas N, et al. Age-dependent association of pulse wave velocity with coronary artery disease and myocardial aging in high-risk patients. J Cardiovasc Med (Hagerstown) 2019; 20(4): 201-9.
[http://dx.doi.org/10.2459/JCM.0000000000000769] [PMID: 30676495]
[11]
Dieden A, Malan L, Mels CMC, et al. Exploring biomarkers associated with deteriorating vascular health using a targeted proteomics chip. Medicine (Baltimore) 2021; 100(20): e25936.
[http://dx.doi.org/10.1097/MD.0000000000025936] [PMID: 34011069]
[12]
Vermeulen B, Schutte AE, Gafane-Matemane LF, Kruger R. Growth differentiating factor-15 and its association with traditional cardiovascular risk factors: The African-PREDICT study. Nutr Metab Cardiovasc Dis 2020; 30(6): 925-31.
[http://dx.doi.org/10.1016/j.numecd.2020.03.001] [PMID: 32278609]
[13]
Andersson C, Enserro D, Sullivan L, et al. Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study. Atherosclerosis 2016; 248: 245-51.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.02.013] [PMID: 26972631]
[14]
Siasos G, Athanasiou D, Terzis G, et al. Acute effects of different types of aerobic exercise on endothelial function and arterial stiffness. Eur J Prev Cardiol 2016; 23(14): 1565-72.
[http://dx.doi.org/10.1177/2047487316647185] [PMID: 27121699]
[15]
McEniery CM, Yasmin IR, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol 2005; 46(9): 1753-60.
[http://dx.doi.org/10.1016/j.jacc.2005.07.037] [PMID: 16256881]
[16]
Thijssen DHJ, Black MA, Pyke KE, et al. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol 2011; 300(1): H2-H12.
[http://dx.doi.org/10.1152/ajpheart.00471.2010] [PMID: 20952670]
[17]
Buljubasic N, Vroegindewey MM, Oemrawsingh RM, et al. Temporal pattern of growth differentiation factor-15 protein after acute coronary syndrome (From the BIOMArCS Study). Am J Cardiol 2019; 124(1): 8-13.
[http://dx.doi.org/10.1016/j.amjcard.2019.03.049] [PMID: 31047655]
[18]
Rueda F, Lupón J, García-García C, et al. Acute-phase dynamics and prognostic value of growth differentiation factor-15 in ST-elevation myocardial infarction. Clin Chem Lab Med (CCLM) 2019; 57(7): 1093-101.
[http://dx.doi.org/10.1515/cclm-2018-1189] [PMID: 30707681]
[19]
Tzikas S, Palapies L, Bakogiannis C, et al. GDF-15 predicts cardiovascular events in acute chest pain patients. PLoS One 2017; 12(8): e0182314.
[http://dx.doi.org/10.1371/journal.pone.0182314] [PMID: 28771550]
[20]
Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P. Relation of growth-differentiation factor 15 to left ventricular remodeling in ST-segment elevation myocardial infarction. Am J Cardiol 2011; 108(7): 955-8.
[http://dx.doi.org/10.1016/j.amjcard.2011.05.028] [PMID: 21784389]
[21]
Patsalos A, Halasz L, Medina-Serpas MA, et al. A growth factor–expressing macrophage subpopulation orchestrates regenerative inflammation via GDF-15. J Exp Med 2022; 219(1): e20210420.
[http://dx.doi.org/10.1084/jem.20210420] [PMID: 34846534]
[22]
Kempf T, Zarbock A, Widera C, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 2011; 17(5): 581-8.
[http://dx.doi.org/10.1038/nm.2354] [PMID: 21516086]
[23]
Agewall S, Beltrame JF, Reynolds HR, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J 2017; 38(3): 143-53.
[PMID: 28158518]
[24]
Ben Ahmed H, Allouche E, Chetoui A, et al. Relationship between arterial stiffness and the severity of coronary artery disease in acute coronary syndrome. Ann Cardiol Angeiol (Paris) 2021; 70(1): 33-40.
[http://dx.doi.org/10.1016/j.ancard.2020.11.006] [PMID: 33256951]
[25]
Muroya T, Kawano H, Koga S, Ikeda S, Yamamoto F, Maemura K. Aortic stiffness is associated with coronary microvascular dysfunction in patients with non-obstructive coronary artery disease. Intern Med 2020; 59(23): 2981-7.
[http://dx.doi.org/10.2169/internalmedicine.5401-20] [PMID: 33268696]
[26]
Nichols WW, Denardo SJ, Davidson JB, Huo T, Bairey Merz CN, Pepine CJ. Association of aortic stiffness and wave reflections with coronary flow reserve in women without obstructive coronary artery disease: An ancillary study from the National Heart, Lung, and Blood Institute–sponsored Women’s Ischemia Syndrome Evaluation (WISE). Am Heart J 2015; 170(6): 1243-54.
[http://dx.doi.org/10.1016/j.ahj.2015.08.019] [PMID: 26678647]
[27]
Mourouzis K, Siasos G, Oikonomou E, et al. Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease. Lipids Health Dis 2021; 20(1): 12.
[http://dx.doi.org/10.1186/s12944-021-01438-4] [PMID: 33583415]
[28]
Tanrıkulu O, Sarıyıldız MA, Batmaz İ, et al. Serum GDF-15 level in rheumatoid arthritis: relationship with disease activity and subclinical atherosclerosis. Acta Reumatol Port 2017; 42(1): 66-72.
[PMID: 27679935]
[29]
Bao X, Xu B, Borné Y, et al. Growth differentiation factor-15 and incident chronic kidney disease: a population-based cohort study. BMC Nephrol 2021; 22(1): 351.
[http://dx.doi.org/10.1186/s12882-021-02558-w] [PMID: 34706669]
[30]
Wang K, Zelnick LR, Anderson A, et al. Cardiac biomarkers and risk of mortality in CKD (the CRIC Study). Kidney Int Rep 2020; 5(11): 2002-12.
[http://dx.doi.org/10.1016/j.ekir.2020.08.028] [PMID: 33163721]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy